MCO-010

About Nanoscope Therapeutics

Nanoscope Therapeutics is pioneering a next-generation, ambient light-activated optogenetic platform to treat blindness caused by retinal degenerations. Its lead asset, MCO-010, has demonstrated vision restoration in clinical trials for patients with Retinitis Pigmentosa and is positioned as a potential first-in-class, broad-spectrum therapy. The company has secured significant regulatory designations, including Orphan Drug and Sakigake status in multiple regions, underscoring the high unmet need and potential expedited pathways for its programs. Nanoscope represents a compelling player in the retinal gene therapy space with a platform technology that could address multiple diseases without requiring specific genetic mutations.

About Nanoscope Therapeutics

Nanoscope Therapeutics is pioneering a next-generation, ambient light-activated optogenetic platform to treat blindness caused by retinal degenerations. Its lead asset, MCO-010, has demonstrated vision restoration in clinical trials for patients with Retinitis Pigmentosa and is positioned as a potential first-in-class, broad-spectrum therapy. The company has secured significant regulatory designations, including Orphan Drug and Sakigake status in multiple regions, underscoring the high unmet need and potential expedited pathways for its programs. Nanoscope represents a compelling player in the retinal gene therapy space with a platform technology that could address multiple diseases without requiring specific genetic mutations.

Therapeutic Areas

Other Retinitis Pigmentosa Drugs